Weekly Research Analysts’ Ratings Updates for Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE: NVO) recently received a number of ratings updates from brokerages and research firms:

• 11/28/2025 – Novo Nordisk A/S had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $60.00 to $54.00. They now have a “buy” rating on the stock.
• 11/25/2025 – Novo Nordisk A/S had its price target lowered by analysts at BMO Capital Markets from $50.00 to $46.00. They now have a “market perform” rating on the stock.
• 11/24/2025 – Novo Nordisk A/S was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
• 11/24/2025 – Novo Nordisk A/S was downgraded by analysts at Hsbc Global Res from a “strong-buy” rating to a “hold” rating.
• 11/24/2025 – Novo Nordisk A/S was downgraded by analysts at HSBC Holdings plc from a “buy” rating to a “hold” rating.
• 11/17/2025 – Novo Nordisk A/S had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Novo Nordisk A/S had its “market perform” rating reaffirmed by analysts at BMO Capital Markets.
• 11/11/2025 – Novo Nordisk A/S had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/5/2025 – Novo Nordisk A/S was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
• 10/27/2025 – Novo Nordisk A/S is now covered by analysts at Jefferies Financial Group Inc.. They set an “underperform” rating on the stock.
• 10/14/2025 – Novo Nordisk A/S had its “market perform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $55.00 price target on the stock, up previously from $50.00.
• 10/14/2025 – Novo Nordisk A/S had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.